

RNS Number : 2438G  
EKF Diagnostics Holdings PLC  
11 March 2024

**EKF Diagnostics Holdings plc**  
("EKF", the "Company", or the "Group")

**Notice of Full Year Results and Investor Presentation**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, will announce its full year results for the year ended 31 December 2023, on Wednesday 20 March 2024.

**Investor Presentation**

Julian Baines, Executive Chair, and Stephen Young, Chief Financial Officer, will be hosting a live online presentation relating to the Full Year results via the Investor Meet Company platform at 4:30pm on Wednesday 20 March 2024. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:

<https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor>

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.

A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

**EKF Diagnostics Holdings plc** [www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
Julian Baines, Executive Chair / Stephen Young, CFO **Tel: +44 (0)29 2071 0570**

**Singer Capital Markets (Nominated Adviser & Joint Broker)** **Tel: +44 (0)20 7496 3000**  
Aubrey Powell / Oliver Platts

**Walbrook PR Limited** **Tel: +44 (0)20 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)**  
Paul McManus / Charlotte Edgar **Mob: +44 (0)7980 541 893 / +44 (0)7884 664 686**

**About EKF Diagnostics Holdings plc** ([www.ekfdiagnostics.com](http://www.ekfdiagnostics.com))

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORFIFEAVEIAIIS Anonymous (not verified) Notice of Results and Investor Presentation 34144006  
A Mon, 03/11/2024 - 07:00 LSE RNS Advance Notice of Results EKF